The occurrence of deep vein thrombosis (DVT) in gynecologic cancer patients has a multifactorial genesis.
phylaxis with either a daily dose of low molecular weight heparin (LMWH) administered subcutaneously or oral anticoagulation with warfarin was given (9) (10) (11) . In a recent postmortem study (12) , among 966 consecutive autopsies with thrombosis and/or pulmonary embolism (PE), cancer was coincident in 56% of cases. Breast cancer (5.7%) and cervical cancer (2.4%) were among the four most frequent cancer types and were significantly over represented when compared to a control group of 325 consecutive and unselected autopsies without DVT (3.1 % and 0.6%; p < .05).
The most comprehensive data on thrombotic complications in gynecologic malignancy were drawn from studies of breast cancer patients in association with cytoreductive therapy and showed an approximate average incidence of 5%. These results are substantial since most patients with breast and ovarian cancer will receive chemotherapy for adjuvant and/or palliative settings some time in the course of their disease.
Deep vein thrombosis is a frequent complication in gynecologic malignancy and should be considered when planning therapeutic management of patients. This article discusses the prethrombotic state and the rate of thrombotic complications in patients receiving standard cytoreductive therapy for breast and ovarian cancer and the possible mechanisms of chemotherapy-induced thrombosis. The results of recent thrombosis prevention trials are summarized.
BLOOD COAGULATION ACTIVATION IN GYNECOLOGIC CANCER PATIENTS
In previously untreated gynecologic cancer patients systemic coagulation activation is stage dependent, and it can be triggered by several unspecific mechanisms. At diagnosis, the median age of breast cancer patients is 57 and 61 for ovarian cancer patients (13) . This reflects a higher prevalence of atheriosclerotic changes of vessels and insufficient venous valve function that is associated with a reduced endothelial anticoagulant activity and blood flow, and is accompanied by an increased fibrinogen turnover (14) . In addition, the inflammatory response of the monocyte/macrophage system to benign and malign tumors results in thrombin formation (15) (16) (17) .
According to the &dquo;Registry on Human Tumor Proco-agulants&dquo; of the Scientific and Standardization Committee Communication ( 18) , a number of tumor types also provide specific coagulation initiating features that principally induce thrombin formation via direct activation of factor VII or X. Tissue Factor (TF), the classical initiator of the extrinsic pathway, is one of the most frequent tumor procoagulants and was traceable in a functional intact form in ovarian cancer (19) and more recently, in the endothelium of breast cancer while not in benign breast tumor tissue (20) . In addition, TF is believed to play a key role in the stimulation of tumor neoangiogenesis (21) . Breast (22) and ovarian cancer (23) tissues show significantly increased levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-I (PAI-1 ) compared to the corre-sponding benign tumor tissues with two and four times higher uPA and PAI-1 concentrations in peritoneal metastasis in advanced ovarian malignancy (24) . Ovarian cancer cells seem to produce and release PAI-1 into the blood circulation (25). This mechanism might also account for elevated plasma PAI-1 antigen levels and activities found in studies on breast cancer (26,27), ovarian cancer (25), colon cancer (28) and miscellaneous cancer types (29, 30) . Whether this leads to impaired systemic fibrinolysis and thus favors DVT development has not yet been studied.
Architecture of tumor vessels may differ in many aspects from that in normal conditions in the way that they are often dilated, tortiours, and saccular and may contain tumor cells within the endothelial lining of the vessel wall (31). The combination of sluggish blood flow, hyperpermeability, and discontinuous endothelial cell layer that may cause presentation of subendothelial adhesion molecules (ligands) and procoagulant substances (e.g., vitronectin, TF) (32), and reduce the anticoagulant capacity of tumor endothelial cells, may transform the tumor vascular system to a focus of chronic coagulation activation. Beside genetic predisposition for DVT such as factor V Leiden mutation, another possible contribution to impaired hemostasis may be the presence of antiphospholipid (APL) and anticardiolipin (ACL) antibodies, which can interact with phospholipid membranes of platelets and endothelial cells and can inhibit protein C, protein S, and prostacyclin activation by endothelial cells as well as anticoagulatory functions of p2-glycoprotein 1 (33,34). While in healthy individuals elevated APL antibody titers are found in 0% to 7.5%, no representative studies exist on the prevalence in cancer patients with solid tumors. In a recent trial the prevalence of increased ACL antibody titers in 216 cancer patients was 22% (n = 47), whereas 28% of ACL antibody-positive patients developed DVT during 12-month follow-up as compared to 14% (p < .05) in ACL antibody-negative patients. Among 20 women with breast cancer and 7 with ovarian cancer the prevalence of increased ACL antibody titers was 15% (n = 3) and 28% (n = 2), respectively (35).
Dissemination of cancer and the great number of antigenic tumor cells may potentially stimulate T-cell/B-cell interactions that might induce APL antibody development as a possible cause for the increasing incidence of DVT in advanced malignancy. (37) could demonstrate that the extent of preexisting coagulation activation in cancer patients prior to surgery can signal the risk for postoperative DVT as indicated by significantly higher thrombin-antithrombin complexes (TAT), and fibrinogen total degradation products (TDPs) in patients who did versus did not develop DVT. At primary diagnosis of ovarian malignancy commonly the presence of pithy D-dimer and fibrinogen elevation in plasma, asci-tes, and cystic fluid refers to systemic coagulation activation that is significantly more pronounced compared to that found in patients with breast and uterine cancer (38) (39) (40) (41) (42) . The extent in fibrinogen/fibrin turnover significantly correlates with an increase in plasma viscosity that together with modest anemia produces a hematocritindependent hyperviscosity syndrome that can be predictive for the development of postoperative DVT in ovarian cancer patients (43) . High-fibrinogen concentrations can lead to a nonspecific and reversible binding of fibrinogen to red blood cell (RBC) membrane glycoproteins that favors bridging (aggregation) of adjacent RBCs via hydrogen bonds (43) . The high &dquo;fibrinogen load&dquo; on the erythrocyte membrane not only induces RBC aggregation but also decreases cell deformability which together with a high-plasma viscosity can reduce blood flow and oxygen transport capacity in the low-shear region of the postcapillary venous system (44) . Low-blood flow facilitates adhesion of blood cells at the vessel wall and reduces shear stress, further inhibiting disaggregability of RBC and platelets (43) . Local hypoxia especially behind the valve pockets can induce the release of adenosine diphosphate (ADP) and proteolytic substances from stagnant leukocytes, the latter of which may damage endothelium (45, 46) . Activation of platelets (e.g., by ADP) and accumulation of activated coagulation factors (such as factors IXa or Xa) with thrombin formation may contribute to thrombogenesis (46) . This complex set of circumstances might explain why the preoperative plasma viscosity is associated with subsequent thrombosis (42, 44, 47) . Recently it was shown that neither preoperative levels of D-dimer, fibrinogen antithrombin, protein C, and PAI activity, nor the FIGO (International Federation of Gynecology and Obstetrics) stage of the ovarian malignancy were predictive for DVT postoperatively or during chemotherapy (39, 40) . In patients with previously untreated nonmetastatic breast cancer, markers of fibrin formation (fibrinopeptide A [FPA], fibrinogen, TAT), and fibrinolysis (fibrin fragment 13 15-42 , D-dimer) are significantly increased compared to healthy individuals but similar compared to the levels in benign breast tumor patients (40, 41, (48) (49) (50) (51) . Dissemination of breast cancer, however, is accompanied by a significant rise of these markers but it is not known if this feature is an increased risk for DVT (52) . 
THROMBOSIS INCIDENCE
A major problem in the diagnosis of DVT is the low clinical appearance of <55% and the misinterpretation of symptoms. The quality of any thrombosis trial is a function of screening procedures (i.e. standardized diagnostic methods) and method for estimating event rates over time (53) . Moreover, in practice it is still not generally accepted that there is a connection between chemotherapy and thrombosis (57, 59) . Thus if someone does not expect thrombosis to occur he/she will rarely recognize it. These considerations together with the increased ambulatory handling of patients (that reduces patients surveillance) may account for the fact that in most cytoreductive treatment trials thrombotic events do not seem to play a role.
The following data on DVT incidences are based on trials that described thrombosis as a possible complication of chemotherapy (Table 1 and 2). According to the results of six studies (2, 5, 6, 51, 54, 56) in which a total of 3,101 patients received adjuvant chemotherapy for breast cancer without hormonal supplements (i.e., tamoxifen or medroxyprogesterone acetate [MPA]) thrombotic complications occurred with an average mean incidence of 4.5% (range of means: 1.3-10%). In four of these studies (5, 6, 54, 56) during adjuvant CMF therapy an average mean DVT incidence of 4.2% compared to 4.8% in association with anthracycline regimens was found (2, 5, 51) . During chemotherapy for metastatic breast cancer disease in four studies of 334 patients (58) (59) (60) (61) the average mean DVT incidence was 9.8%, respectively.
In four studies during concurrent tamoxifen and chemotherapy for nonmetastatic breast cancer in 1,102 patients (6,54,63,64) an average mean DVT incidence of EC, 5 fluorouracil/epirubicin/cyclophosphamide; CMF, cyclophosphamid/methotrexat/fluorouacil; AC, adriamycin/cyclophosphamid; EC, epirubicin cyclophosphamid; FPA, fibrinopeptide A; aPTT, activated partial thromboplastin time; PT, prothrombin time; TAT, thrombin-antithrombin complex; PIP, plasmin-inhibitor plasminogen; PAI-1, plasminogen activator inhibitor type 1; TPA, tissue plasminogen activator; TT, thrombin time; RBC, red blood cell; INR, International Normalized Ratio; ag, antigen; act, activity; VP, vincristine/prednisone. 4 .8% (range of means: 3.1-9.3%) was recorded. This is more than twice as high as compared to the average mean rate of 1.7% (range of means: 0-5.6%) found in eight studies during tamoxifen mono therapy based on a total of 3,184 patients without metastasis (7, 54, 63, 64, (67) (68) (69) (70) . Tamoxifen or toremifen mono therapy for metastatic breast cancer in 3,370 patients from five studies (71) (72) (73) (74) (75) revealed no increased rate for DVT (average mean DVT incidence 2.1%; range of means: 0.8-3.2%) compared to adjuvant tamoxifen mono therapy. A representative trial by the Stockholm Breast Cancer Study Group found no significant differences in the incidence of hospital admissions due to DVT in 2,365 postmenopausal patients who were randomly assigned to either adjuvant tamoxifen treatment (49/1188; 4.1%) (94) . In six studies the use of high-dose MPA mono therapy (500-1200 mg/die) including 1,225 patients with metastatic breast cancer was associated with an average mean DVT rate of 4.06% (72-75,77-79,94) (range of means: 0.9-14.5%) compared to 4.13% (range of means: 3.5-4.7%) in 407 patients from four studies (82) (83) (84) (85) receiving megestrol ac-
During platinum-based chemotherapy in two studies including 130 patients with ovarian cancer a DVT incidence of 10.6% and 12.0%, respectively, was recorded (39,66).
BLOOD COAGULATION AND BLOOD RHEOLOGY DURING CYTOREDUCTIVE TREATMENT

Chemotherapy
Studies that dealt with possible causes of chemotherapy-related DVT in breast and ovarian cancer revealed no clear pattern of hemostaseological or hemorrheological disorders, or changes were moderate and not accompanied by DVT (Tables 3,4 ). Thrombogenic potential of substances used for cytoreductive treatment in gynecologic malignancy has been investigated in vivo and in vitro. Figure 1 shows a flow chart of the results. However, at present proof of chemotherapy-induced DVT does not exist for the adduced mechanisms.
With reference to the investigations by Bertomeu (104) chemotherapeutic substances can directly interact with blood cells and endothelium that may cause hemostaseological imbalance in vivo. Preincubation of human umbilical cell (HES) with plasma samples of 15 patients with stage II breast cancer obtained 15 minutes after administration of epirubicin/5fluorouracil/cyclophosphamid chemotherapy significantly increased the number of adherent platelets to HES of about 60% over the rate observed after incubation with plasma obtained before chemotherapy (86) . Because platelet adhesion was significantly correlated with an increase in interleukin-1 activity (r = 0.86; p < .001) and was blocked by antibodies to vitronectin, it was postulated that chemotherapeutic substances stimulate the release of endogenous interleukin-1 that induces expression of the vitronectin receptor on the endothelial cell surface. Blood samples from 56 patients who had been receiving CMF chemotherapy with or without radiation for stage III breast cancer contained significantly lower levels of phospholipids (p < .001), while cholesterol was significantly increased (p < .05) as compared to patients without chemotherapy (102) . The authors speculated that this significant increase in cholesterol:phospholipid (C:P) ratio (0.82; p < .001) in plasma may be the result of chemotherapy-induced formation of free radicals that hydrolyze unsaturated bonds of fatty acid chains in phospholipids and produce acetate, which is the initial component for cholesterol synthesis. Beside movement of cholesterol from plasma to cell membranes the formation of free radicals might also directly induce damage of erythrocyte membranes leading to an increased membrane C:P ratio and thus to reduced cell deformability, which was observed in another study of breast cancer patients after CMF treatment (103) . However, corre-sponding investigations in vitro did not reveal any diminished deformability of erythrocytes when incubated with anthracyclines such as adriamycin (104) . In 49 patients with stage II breast cancer during 12 courses of adjuvant chemotherapy of a CMF vincristin combination regimen alternated with adriamycin and cyclophosphamid (AC) (n = 12) or of CMF therapy alone, respectively (n = 37), Canobbio et al. (91) demonstrated a significant decrease in partial thromboplastin time (PTT) and thrombin time (TT) although the latter remained in the normal range. Goodnough and coworkers (60) performed single coagulation factor assays in a subgroup of 10 of 159 patients who were being treated with CMF vincristin prednisone chemotherapy for stage IV breast cancer and found that PT was significantly lower while factor VIII Ag:R was significantly higher (p < .05) as compared to the results in ten patients who had completed chemotherapy. In a study by Rogers et al. (88) , in seven women with and eight without metastatic breast cancer receiving CMF regimen for 1 month, protein C (p < .01) and protein S (p < .01) antigen levels as well as activities significantly decreased on days 8, 15 , and 29 of therapy as compared to the initial values. Feffer et al. (89) found that in six women receiving six cycles of adjuvant hormonal/CMF combination therapy and in three patients with advanced breast cancer receiving CMF regimen alone until disease progression had a significant and uniform decline in protein C activity 2 months after the commencement of chemotherapy. These results have recently been reinforced by Rella et al. (90) who noted a significant reduction for protein C and S levels and activities (p < .O 1 ) soon after the beginning of six cycles of adjuvant CMF therapy in 38 patients with breast cancer while antithrombin levels remained unchanged. PAI antigen levels significantly increased after therapy was started and remained above normal (p < .06) throughout chemotherapy. However, neither TAT, Ddimer nor prothrombin fragment Fl + 2 significantly changed and the authors concluded that CMF therapy did not initiate disseminated intravascular coagulation (DIC). This view is supported by a study in which serial coagulation assays performed before each of six cycles procoagulant activity; TPA, tissue plasminogen activator; uPA, urokinasetype plasminogen activator; PAI-1, -2, plasminogen activator inhibitor type I or type 2; aPTT, activated partial thromboplastin time, PT, prothrombin time; TT, thrombin time; AC, adriamycin/cyclophosphamid; MPA, medroxyprogesterone acetate; PIP, plasmin inhibitor plasminogen; FDP, fibrinogen degradation products; CT, chemotherapy; JABCS, Japan Advanced Breast Cancer Study Group; ag, antigen; act, activity. of adjuvant epirubicin/cyclophosphamide (EC) chemotherapy in 50 consecutive patients with breast cancer (T» NO-2 M,) revealed no changes for protein C and antithrombin while mean D-dimer (p = .008) and fibrinogen levels were significantly lower after the first and each following cycle (p < .0001) (51). However, patients experiencing DVT during chemotherapy had significantly higher D-dimer levels (p < .0001) preoperatively as compared to patients without DVT. Interestingly, mean PAI activity remained above normal before and after surgery throughout chemotherapy and it was concluded that the significantly lower PAI activities 3 months after chemotherapy might refer to the effect of chemotherapy on tumor reduction. In most of these patients (n = 43) rheological measurements were also per-formed. Although before surgery and before the beginning of chemotherapy mean values of RBC aggregation under conditions of stasis or low shear and plasma viscosity were significantly higher compared to a control group of 72 healthy women, none of these parameters was found to further increase during chemotherapy (92) . Altogether five (10%) patients developed DVT compared to none in the aforementioned studies. A reduction in mean protein C levels during nine cycles of chemo- received CMF (n = 11). By contrast, protein C levels remained unchanged in a control group of 16 patients who concomitantly received warfarin thrombosis prophylaxis. Wieding and colleagues (93) found no differences in mean antithrombin levels and activities in 57 women with advanced breast cancer before, compared to after, receiving one cycle of different chemotherapy regimens. During five cycles of cisplatinum doxorubicin 5 fluorouracil chemotherapy in 26 ovarian cancer patients in FIGO stage III and IV Mirshahi et al. (105) serially determined D-dimer where mean levels decreased in 8 patients but remained unchanged and above normal in 18. No information about DVT was given. In a study of 47 patients with ovarian malignancy of FIGO stage Ib-IV during six cycles of first line PEC chemotherapy (cisplatinum and EC) compared to the levels before surgery and before chemotherapy mean D-dimer and fibrinogen levels significantly decreased. This was accompanied by a normalization of plasma viscosity while PAI activity increased and protein C, antithrombin, and RBC aggregation (stasis and low shear) remained unchanged. DVT occurred in three patients after the first, in one patient after the second, and in another patient after the fourth cycle of chemotherapy (39,95).
The major conclusion drawn from the results of these trials seems to be that antithrombin is affected by none of the aforementioned chemotherapeutical regimens while a reduction in protein C and S activity/levels is associated with CMF therapy but not with anthracycline regimens. This might be explained by methotrexate-induced inhibition of tetrahydrofolate-dependent synthesis of starter molecules of protein synthesis (e.g. nucleic acids, pyrimidine, and purine). However, this alone does not account for the development of DVT in patients.
-_ _ Tamoxifen
Since thrombosis is an established and widely accepted side effect of hormonal treatment with either tamoxifen or MPA a number of trials have examined possible influences on blood coagulation of these drugs. In the Wisconsin Tamoxifen Study, Love et al. (68) serially determined antithrombin, fibrinogen, and platelet count before therapy, after 3 and 6 months in 140 postmenopausal node-negative women with breast cancer who were randomly assigned to either adjuvant tamoxifen (n = 70; 10 mg orally twice daily) or placebo (n = .99 70). Mean antithrombin levels significantly declined (p = .0001) and levels were significantly lower in the tamoxifen group (p = .0001) compared to those receiving placebo but none of the patients exhibited a decline to clinical significant levels (>70%). While fibrinogen levels only declined during tamoxifen treatment, in both groups platelet count was significantly lower at each estimation time-point compared to the baseline values. Again, these changes were within the normal range. One patient in the tamoxifen group developed superficial thrombophlebitis compared to none in the placebo group. In this study a subgroup of 32 women were also tested for protein C and S levels but a significant reduction was only observed for the levels of protein C after 24 months of tamoxifen treatment (69) . Auger and colleagues (96) found no differences in concentrations of protein C, antithrombin, and FPA in addition to monocyte procoagulant activity (MPCA) in 14 patients with nonmetastatic breast cancer who had received tamoxifen for 3 to 38 months (20 mg, twice daily) compared to those of 15 node-negative patients under observation. In a study by Lox et al. (97) twenty-six patients with breast cancer who had received tamoxifen for 3 to 60 months (10 mg, once daily) tissue plasminogen activator (TPA) (p = .04), uPA (p = .002), and PAI-1 (p = .04) levels were significantly higher compared to 17 breast cancer patients without hormonal treatment while levels of PAI-2 were not different (p = .4). Pemberton and coworkers (7) studied 149 patients with nonmetastatic breast cancer. In this group, 90 women had been previously randomized to receive adjuvant tamoxifen (20 mg once daily) for at least 2 years. Eighteen of the 90 women were still on medication and another 60 comprised a control group without tamoxifen therapy. No significant differences were observed between groups in global clotting times (aPTT, PT, TT), fibrinogen levels, fibrinolytic factors (TPA antigen/activity, PAI activity, plasminogen, a2 antiplasmin) or main anticoagulant concentrations (antithrombin, protein C, S ag/act). By contrast, current users had significantly lower antithrombin (p < .05), protein C activity (p < .05) in addition to higher levels of plasminogen (p < .O 1 ) and TPA ag (p < .O l ) compared to former users. Four patients had DVT after termination of tamoxifen therapy and one of the current users (5.62%). It was hypothesized that a reduction in anticoagulants by tamoxifen might be the cause of DVT. In a comparative neoadjuvant study of oral (n = 6) and percutaneous tamoxifen treatment (n = 22) for 21 days by Pujol et al. (98) antithrombin and fibrinogen levels were significantly lower (p < .05) after the end of oral therapy but unchanged after percutaneous treatment. In a study by Powles et al. (99) women at higher risk for breast cancer were randomized to receive placebo or tamoxifen for a varying time period. A nonsignificant trend towards reduced antithrombin and fibrinogen levels was found in a subgroup of 14 women while under tamoxifen treatment. No thrombotic complications were reported.
In summary, in most trials tamoxifen treatment was associated with a more or less lowering in antithrombin levels that neither reached clinical significance nor was identified as a cause of DVT occurrence.
Medroxyprogesterone acetate
Treatment for metastatic breast cancer is the most common indication of high-dose MPA (>500 mg/day). Although DVT is a well-known side effect, very little is known about its influence on blood coagulation. In a study by the Japan Advanced Breast Cancer Study Group (JABCS) (81), 82 women with advanced breast cancer in addition to AC chemotherapy were randomly assigned to either tamoxifen (20 mg once daily) or MPA therapy (1, 200 mg once daily). Therapy was continued until disease progression and each week coagulation tests were repeated. Compared to the initial values 4 weeks later as well as 52 weeks thereafter antithrombin levels were significantly decreased in the tamoxifen group (p < .01) while during MPA treatment levels of antithrombin and protein C remained significantly increased (p < .01). Fibrinogen levels, TPA and factor X remained within the normal range in both groups. Levels of D-dimer, TAT, a2-plasmin inhibitor plasmin complex (PIP) showed a continuous decline during tamoxifen treatment while these levels, in addition to plasminogen, remained elevated throughout MPA treatment. One patient receiving MPA developed DVT but none of the patients given tamoxifen combination chemotherapy. Serially clotting estimations by Yamamoto et al. (100) revealed that antithrombin, factor II, factor IX, and plasminogen increased significantly (p < .05) during 6 months of MPA therapy (800 mg/day) while factor VII, fibrinogen and aPTT decreased significantly (p < .05) FDP, factors VIII, X, XI, and XII remained unchanged. Deep vein thrombosis occurred in none of the patients. In a placebo controlled study of the MPA Hematology Italian Cooperative Group (101) a subgroup of 26 patients with different types of tumors, including patients with advanced breast cancer, had coagulation estimations before, and 2 months after, onset of high-dose MPA (1,000 mg once daily)/ chemotherapy combination therapy. An increase of antithrombin activity and antigen, plasminogen, and factor IX concentrations was observed. In contrast, in 19 patients who received a placebo instead of MPA, chemotherapy did not lead to any changes in the coagulation tests. However, in this study of 2 (1.7%) of 117 patients receiving MPA compared to 1 (0.9%) of 110 patients in the placebo/chemotherapy group developed DVT. According to these results, it is likely that high-dose MPA treatment induces coagulation activation as indicated by the constant increase of fibrin split products and markers of thrombin formation. Nonetheless, no clear relation-ship emerges from these results with respect to the cause of DVT.
PREVENTION TRIALS
Since the successful introduction of anticoagulation for thrombosis prophylaxis and gynecologic cancer surgery, a small number of studies investigated the effect of long-term anticoagulation on thrombosis during chemotherapy. Prior to these clinical trials, a study by Edwards and colleagues (87) showed that heparin could abolish chemotherapy-induced coagulation activation. In 16 patients receiving different regimens of chemotherapy for various advanced malignancies, a significant increase in mean FPA levels (p < .01) 45 minutes after administration of chemotherapy was found. Seven to 28 days thereafter in eight of these patients single injections of 5,000 IU of unfractionated heparin immediately after blood collection and before chemotherapy resulted in significantly lower FPA levels 45 minutes after chemotherapy (p < .02). The authors concluded that heparin not only reduced chemotherapy and thrombin formation but prevented DVT in patients. This finding should be addressed in larger trials.
Levine and colleagues (58) performed a double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.
Throughout chemotherapy (the kind of which was not mentioned) and until 1 week after, 152 women with metastatic breast cancer received a daily dose of waufarin adjusted to maintain the PTT at an international normalized ratio (INR) of 1.3 to 1.9. A control group of 159 patients with metastatic breast cancer received a placebo instead of warfarin during chemotherapy. In the warfarin group, PE occurred in one (0.65%) patient compared to six women with DVT and one (4.4%) with PE in the placebo group. Thrombosis prophylaxis with warfarin significantly reduced the relative risk for DVT (about 85%, p = .031) while only one patient had major bleeding compared to two patients in the placebo group. In a prospective randomized trial by Falanga et al. (59) , patients with metastatic breast cancer who were treated with nine cycles of CMF (n = 11) or other regimens concomitantly either received very-low-dose warfarin daily adjusted to an INR between 1.3-1.9 (n = 16) for thrombosis prophylaxis or placebo (n = 16). DVT occurred in two women of the placebo group compared to none in the warfarin group. In addition, between the fourth and sixth cycles mean levels of the D-dimer (p = .0028), TAT (p = .0069), and F 1+2 (p = .001) were significantly lower in patients who did versus did not receive warfarin prophylaxis. In a prospective study among 47 patients with ovarian malignancy FIGO stage Ib-IV during six cycles of PEC chemotherapy, 6 patients concomitantly received thrombosis prophylaxis with 3,000 anti-Xa U of LMWH once daily subcutaneously (Certoparin, Novartis, Neurnberg, Germany) due to previous pre-and postoperative DVT. Between the first and fifth cycle of chemotherapy five of the women without prophylaxis developed DVT compared to none of the women who concomitantly received LMWH (39).
Placement of an indwelling long-term central venous catheter may be the last resort to reach venous access for administration of chemotherapy. Since these patients are particularly prone to thrombosis a recent study assessed if long-term administration of a LMWH (once 2,500 IU/ die subcutaneously of Fragmin@, Pharmacia Deltec Inc.) compared to no anticoagulation could reduce the incidence of upper extremity DVT. As the incidence of DVT reached 62% (8/13) in the group without prophylaxis compared to 6% (1/16) during LMWH treatment, this study was terminated earlier than planned (106) .
RECOMMENDATIONS FOR THROMBOSIS PROPHYLAXIS DURING CYTOREDUCTIVE THERAPY
At present, conventional chemotherapy for gynecologic malignancy is not routinely combined with thrombosis prophylaxis and it seems that the majority of patients undergoing chemotherapy will not require prophylaxis. Moreover, general prophylaxis in these patients is cost intensive and in terms of oral anticoagulation needs to be monitored by laboratory methods. The incidence of thrombosis during MPA or tamoxifen treatment compared to chemotherapy is low and therefore hormonal anticancer treatment alone does not justify thrombosis prophylaxis.
The questions to answer are how to identify patients who will benefit from prophylaxis and what kind of prophylaxis should be given. Conventional chemotherapy appears not to significantly impair blood coagulation or rheology, and an increase in coagulation activation alone does not cause thrombosis. Therefore, a search for other risk factors is indicated. In four studies (2, 5, 51, 54) noted in Table 1 on menopausal status, body mass index (BMI), number of positive axillary nodes, hormone receptor status, and the type of preceding surgery were available for a total of 2,377 patients undergoing chemotherapy. In addition, the hazard ration for the development of DVT during chemotherapy was significantly increased in postmenopausal women (HR, 2.01; CI 95%, 1.09-3.70; p = .002), women with previous mastectomy (HR, 3.57; CI 95%, 1.88-6.79; p < .001), and with increased bodyweight (BMI >25 kg/m2; HR, 2.91; CI 95%, 1.71-5.82; p < .001). However, neither the number of positive axillary nodes nor hormonal receptor status was predictive in this regard. According to the results by Iversen et al. (37), Falanga et al. (36) and our own experiences (51) the extent of preexisting coagulation ac-tivation can signal the risk for thrombosis postoperatively and during chemotherapy. Although no cutoff values are presently available for breast cancer patients it is recommended by the author that apart from testing for the presence of activated protein C resistance and antiphospholipid antibodies before the commencement of chemotherapy, blood coagulation tests (e.g. D-dimer, TAT, Fl+2) that assess the extent of coagulation activation should be routinely performed. However, during chemotherapy monitoring of patients using sophisticated blood coagulation tests has not been shown to be of value for predicting DVT. Thrombosis prophylaxis during chemotherapy for breast cancer should be considered in postmenopausal women, after mastectomy, in women with an increased BMI (e.g., >25 Kg/M2), and a preexistence of increased coagulation activation. Apart from patients with an indwelling long-term central venous catheter, bedridden patients, or the presence of a genetic risk (e.g., factor V Leiden mutation, antithrombin deficiency), long-term thrombosis prophylaxis is strongly indicated if all four circumstances coincide.
Thrombosis prophylaxis can be given orally (e.g., very low-dose warfarin) (58, 59) or using LMWH, which is a particularly suitable drug for this indication. Prophylaxis should be started 3 to 4 days before the beginning of chemotherapy and continued throughout chemotherapy. Injections can be easily given by the patient because most of the LMWHs are manufactured with a pen injection refilling system that allows for repeated use. The platelet count should be monitored weekly in the first month to detect heparin-induced thrombocytopenia (HIT) . It should also be noted that the use of anticoagulants, especially LMWHs, in malignancy might constitute a new approach for therapy since a number of recent trials have demonstrated an improvement of cancer outcome with respect to patients overall survival in association with these drugs (42, (107) (108) (109) (110) .
SUMMARY
Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because <55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelling central venous catheter or with port cart) are at a particularly high risk for DVT. This has to be considered when cytoreductive therapy is given. Thrombosis prophylaxis, orally or subcutaneously, should only be considered in a subpopulation of patients who offer a com- 
